A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

Naveen Pemmaraju, Hagop Kantarjian, Tapan Kadia, Jorge Cortes, Gautam Borthakur, Kate Newberry, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Sara Dellasala, Sherry Pierce, Srdan Verstovsek

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences